Clinical Trial Update: The TIME-2b Study: A Study of AKB-9778 (Razuprotafib), a Novel Tie 2 Activator, in Patients With Non-Proliferative Diabetic Retinopathy (NPDR) [Phase 2]

View source ↗

Summary

Phase 2 trial update for AKB-9778 (razuprotafib), a Tie2 activator, in non-proliferative diabetic retinopathy has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonproliferative Diabetic Retinopathy

Drugs mentioned

• AKB-9778

Snippet

Sponsor: EyePoint Pharmaceuticals, Inc. | Conditions: Nonproliferative Diabetic Retinopathy | Phase 2 | Status: COMPLETED | Results posted: 2023-06-27